Adefovir dipivoxil

Drug Profile

Adefovir dipivoxil

Alternative Names: Adesera; Bis-POM PMEA; GS 0840; GS 840; Hepsera; Piv2PMEA

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Institute of Organic Chemistry and Biochemistry (Prague); Rega Institute for Medical Research
  • Developer Columbia University; Gilead Sciences; Institute of Organic Chemistry and Biochemistry (Prague)
  • Class Analgesics; Anti-inflammatories; Antiretrovirals; Phosphonic acids; Purine nucleotides; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; Hepatitis B virus replication inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis B
  • Discontinued HIV infections; Rheumatic disorders

Most Recent Events

  • 27 Feb 2017 Gilead Sciences has patent protection for Adefovir dipivoxil in Europe and USA (Gilead Sciences 10-K, February 2017)
  • 01 Sep 2012 Gilead Sciences completes a phase I/II trial in Hepatitis B (Prevention, Combination therapy) in USA (PO) (NCT01146808)
  • 09 Dec 2005 Launched for Hepatitis B in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top